Abstract: A medical image processing apparatus comprises smoothing circuitry that receives a volumetric medical image data set corresponding to a 3D region of a subject and smooths the volumetric medical image data set to generate a smoothed medical image data set, wherein at least one part of the surface of a structure is represented in the volumetric medical image data set, rendering circuitry that produces a 2D rendered data set from the smoothed medical image data set, curvature calculation circuitry that calculates a respective curvature at each of a plurality of positions on the at least one part of the surface of the structure and smooths the calculated curvatures to obtain smoothed calculated curvatures, and shading addition circuitry that adds shading to the 2D rendered data set in dependence on the smoothed calculated curvatures.

Abstract: An image processing apparatus comprises a data receiving unit configured to receive medical imaging data and a registration unit configured to obtain a registration of the medical imaging data with model-based virtual anatomy data by determining a transformation between a coordinate space of the medical imaging data and a coordinate space of the virtual anatomy data based on the locations of anatomical landmarks in the medical imaging data and the locations of corresponding anatomical landmarks in the virtual anatomy data.

Abstract: Use of 2,3-dihydroquinazolin-4(1H)-one cyclic derivatives of formula (I) for the treatment of infection with viruses entering cells by endocytosis, especially filovirus such as Ebolavirus.

Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.

Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.

Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.

Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.

Abstract: A method of navigating along a biological object with a lumen represented by a three-dimensional volume data set comprises generating a plurality of navigation segments connectable in a sequence, each segment having a start point within the lumen, a direction and a length. The navigation may be used for a camera in a virtual endoscopic examination, for example. The direction of each segment is determined by casting groups of rays outwards from the start point of the segment to the object wall, and calculating an average ray length for each group. The group having the largest average ray length is selected, and the axial direction of this group is used as the direction for the segment. The average ray lengths of the groups may be weighted using the direction of the previous segments to bias the navigation generally forward, or may be weighted using a view direction of the camera to allow a user to turn the camera into a chosen branch in the object.

Abstract: The present invention discloses method to coat nanoparticles with viral envelope containing specific proteins. The present invention also discloses that such viral envelope coated nanoparticles can be targeted to specific cells and cellular entry pathway, thereby permitting their use as vaccines, in targeted delivery of therapeutic products and in the study of virus adsorption, cell penetration and viral entry pathways.

Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.

Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.

Abstract: A drive gear assembly is disclosed. The assembly includes a drive shaft (11) and a drive gear (9) mounted on or integral with a drive shaft and rotatable therewith and being adapted to mesh with a driven gear (7). The assembly also includes a self-aligning assembly that supports the drive shaft for rotation about an axis of the drive shaft and so that the drive gear can self-align with respect to the driven gear.

Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins that would deliver the enzyme into the viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.

Abstract: A method of navigating along a biological object with a lumen represented by a three-dimensional volume data set comprises generating a plurality of navigation segments connectable in a sequence, each segment having a start point within the lumen, a direction and a length. The navigation may be used for a camera in a virtual endoscopic examination, for example. The direction of each segment is determined by casting groups of rays outwards from the start point of the segment to the object wall, and calculating an average ray length for each group. The group having the largest average ray length is selected, and the axial direction of this group is used as the direction for the segment. The average ray lengths of the groups may be weighted using the direction of the previous segments to bias the navigation generally forward, or may be weighted using a view direction of the camera to allow a user to turn the camera into a chosen branch in the object.

Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.

Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins that would deliver the enzyme into the viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.

Abstract: The present invention provides collections of polypeptides, where each polypeptide includes a region Xaan, wherein n is from about 5 to about 21, and each Xaa is independently a random amino acid. Polynucleotides encoding the polypeptides, are also provided, as are methods for identifying a polypeptide within a collection that prevents cell death after exposure to a pathogen or a toxin, and methods for identifying a polypeptide within a collection that binds a pathogen, a toxin, a polypeptide, or a polynucleotide. The present invention also provides methods for crystallizing a polypeptide.